Management of Acute Variceal Bleeding and Hepatorenal‑Syndrome AKI in Cirrhosis
1. Acute Variceal Bleeding – Octreotide Preferred
1.1 Choice of Vasoactive Agent
- Octreotide is recommended as the first‑line vasoactive drug for acute variceal bleeding because it has a markedly better safety profile, even though terlipressin is the only agent shown to lower bleeding‑related mortality. [1][2]
1.2 Comparative Efficacy
- Meta‑analyses demonstrate no statistically significant differences between terlipressin and octreotide regarding overall mortality, hemostasis rates, early (≤ 5 days) or late (> 5 days) re‑bleeding, blood‑product requirements, or length of hospital stay. [1][3]
1.3 Safety Profile
- Adverse events occur 2.39‑fold more often with terlipressin than with octreotide. 1
- Reported terlipressin complications include hyponatraemia, myocardial ischaemia from coronary vasoconstriction, abdominal or chest pain, diarrhoea, and respiratory failure. [1][4]3
- Octreotide‑related side‑effects are generally milder (nausea/vomiting, abdominal pain, headache, hyperglycaemia). 4
1.4 Dosing Regimen (Octreotide)
- Initial bolus: 50 µg IV (repeatable within the first hour if bleeding persists).
- Continuous infusion: 50 µg / h IV, continued for 2–5 days after successful endoscopic haemostasis. [1][2]
1.5 Alternative Regimen (Terlipressin) – when Octreotide unavailable
- First 48 h: 2 mg IV every 4 h until bleeding is controlled.
- Maintenance: 1 mg IV every 4 h.
- Total duration 2–5 days. [1][2]
1.6 Essential Triple Therapy
- Vasoactive drug – octreotide preferred; start immediately on suspicion of variceal bleed, even before endoscopy. [1][2]
- Prophylactic antibiotics – ceftriaxone 1 g IV daily for up to 7 days to lower mortality, infection, and re‑bleeding rates. [4][3]
- Endoscopic variceal ligation – performed within 12 hours of presentation. 4
1.7 Treatment Duration in Low‑Risk Patients
- In selected patients (Child‑Pugh A or B and no active bleeding seen on endoscopy) the vasoactive course may be shortened to 2 days; otherwise continue the full 2–5 day course. [1][3]2
2. Hepatorenal‑Syndrome AKI – Terlipressin Preferred
2.1 Choice of Agent
- Terlipressin, combined with albumin, is the recommended vasoactive therapy for HRS‑AKI in cirrhosis. [2][5]
2.2 Comparative Efficacy
- Terlipressin + albumin is more effective at achieving HRS reversal than the midodrine/octreotide regimen or norepinephrine. 6
2.3 Dosing Regimen (Terlipressin)
| Phase | Dose | Frequency | Total Daily Dose | Notes | |
|---|---|---|---|---|---|
| Initial | 1 mg IV | Every 4–6 h | 4–6 mg/day | Start when HRS‑AKI diagnosed | |
| Escalation (if serum creatinine ↓ < 25 % after 2–3 days) | 2 mg IV | Every 4–6 h | 8–12 mg/day (max) | Continue until response | |
| Duration | – | – | – | Up to 14 days or until complete renal response | [6][5][2] |
2.4 Albumin Co‑administration
- Give 20–40 g/day IV albumin concomitantly; this is essential for therapeutic effect. 2
- Monitor closely for pulmonary oedema, especially in patients with cirrhotic cardiomyopathy or diastolic dysfunction. 5
2.5 Contra‑indications
| Type | Contra‑indication | Evidence |
|---|---|---|
| Absolute | SpO₂ < 90 % (hypoxemia) | [2][5] |
| Ongoing coronary ischaemia | [2][5] | |
| Active peripheral‑vascular ischaemia | [2][5] | |
| Active mesenteric ischaemia | [1] | |
| Relative / Caution | ACLF grade 3 | [2][5] |
| Baseline serum creatinine > 5 mg/dL (limited benefit) | [2][5] | |
| Liver‑transplant candidates with MELD ≥ 35 | [2][5] |
2.6 Predictors of Positive Response
- Baseline bilirubin < 10 mg/dL is associated with higher likelihood of HRS reversal. 6
2.7 Administration Considerations
- Terlipressin can be delivered via a peripheral IV line; ICU‑level monitoring is not required. [2][5]
- Continuous infusion (4 mg over 24 h) provides equivalent efficacy with lower total daily dose and fewer adverse events compared with intermittent bolus dosing. 1
2.8 Safety Monitoring
- Respiratory failure occurs in ≈ 14 % of patients receiving terlipressin (vs 5 % with placebo), particularly in ACLF‑3 patients. 5
3. Common Pitfalls (Evidence‑Based Recommendations)
3.1 Acute Variceal Bleeding
- Do not postpone vasoactive drug initiation awaiting endoscopy – start immediately on suspicion of bleed. 1
- Do not omit prophylactic antibiotics – they independently reduce mortality. 1
- Do not use terlipressin as first‑line when octreotide is available, because of its inferior safety profile. 1
3.2 Hepatorenal‑Syndrome AKI
- Do not employ the octreotide/midodrine combination – it is less effective than terlipressin + albumin. 5
- Do not give terlipressin without concurrent albumin – albumin is essential for therapeutic effect. 5
- Do not use vasoconstrictors for non‑HRS AKI in cirrhosis – indication is limited to HRS‑AKI. 2
- Do not overlook volume status – excess albumin can precipitate respiratory failure in patients with diastolic dysfunction. 5
Variceal Bleeding and Hepatorenal Syndrome Management
Clinical Context
- The American Association for the Study of Liver Diseases recommends octreotide as first-line therapy for variceal hemorrhage due to its safety profile, despite terlipressin being the only vasoactive agent proven to reduce bleeding-related mortality in meta-analyses 7, 8
- Meta-analyses demonstrate no significant differences between terlipressin and octreotide in mortality, hemostasis rates, early rebleeding, late rebleeding, blood transfusion requirements, or hospital length of stay 8
- Both agents achieve comparable bleeding control when combined with endoscopic therapy (77% hemostasis at 5 days with combination therapy versus 58% with endoscopy alone) 8
- Terlipressin shows mortality benefit compared to placebo (RR 0.66, 95% CI 0.49-0.88), but direct comparison with octreotide reveals no superiority 9, 8
Safety Profile
- Adverse events occur 2.39-fold more frequently with terlipressin compared to octreotide 8
- Terlipressin causes hyponatremia, myocardial ischemia due to coronary vasoconstriction, abdominal pain, chest pain, diarrhea, and respiratory complications 7, 8
- Octreotide's side effects are milder: nausea/vomiting, abdominal pain, headache, hyperglycemia, and hypoglycemia 7, 8
Dosing Regimens
- Octreotide: 50 μg IV bolus (can repeat in first hour if bleeding continues), followed by continuous infusion at 50 μg/hour for 2-5 days 7, 10, 8
- Terlipressin: 2 mg IV every 4 hours for first 48 hours until bleeding controlled, then 1 mg IV every 4 hours for maintenance, total duration 2-5 days 7, 10, 8
Combination Therapy Algorithm
- Immediate initiation of vasoactive therapy (octreotide preferred) as soon as variceal bleeding is suspected, even before endoscopic confirmation 7, 8
- Prophylactic antibiotics (ceftriaxone 1 g IV every 24 hours for up to 7 days) started simultaneously to reduce mortality, bacterial infections, and rebleeding 9, 10, 8
Hepatorenal Syndrome
- The American Association for the Study of Liver Diseases recommends terlipressin as the vasoactive drug of choice for hepatorenal syndrome, combined with albumin, accounting for the patient's volume status 7
- Terlipressin is the only vasoactive agent with proven efficacy in randomized trials for HRS, reversing type 1 HRS in 33-60% of cases 7
- Terlipressin combined with albumin is more efficacious than alternative regimens (midodrine/octreotide or norepinephrine) for HRS reversal 7
Regulatory and Availability Considerations
- Octreotide is the only vasoactive drug available in the United States for variceal bleeding, making it the de facto choice regardless of comparative efficacy 10, 8
- Terlipressin was recently FDA-approved specifically for hepatorenal syndrome but remains unavailable or restricted for variceal bleeding in many U.S. centers 8